Background: Cognitive impairment has been reported in a significant proportion of patients with congenital muscular dystrophies (CMD), generally associated with brain changes.
associated with structural brain changes, it has also been found in a number of patients with normal brain MRI. 13, 14 Cognitive impairment has also been recently reported in patients with normal ␣-DG and laminin ␣2 expression. 15 No systematic study has been performed to define the frequency of the different forms of CMD and cognitive impairment.
The aim of our study was to establish 1) the overall prevalence of CMD and cognitive impairment in the Italian population; 2) the frequency of individual genetically defined forms; 3) the presence of distinct phenotypes not associated with mutations in the known genes.
METHODS Standard protocol approvals, registrations, and patient consents. The study was approved by the Ethics Committees of each center and informed consent was obtained from all subjects.
Patients. The cohort included patients from all the main tertiary pediatric neuromuscular centers in Italy. In order to establish the prevalence of cognitive impairment in patients with CMD in Italy, we considered the total number of patients in the CMD database of the participating centers and among those we selected the patients who fulfilled the inclusion criteria. Inclusion criteria were 1) diagnosis of CMD with early presentation (neonatal or delayed acquisition of early milestones) and myopathic/dystrophic changes on muscle biopsy, and 2) presence of cognitive difficulties.
Patients were initially classified taking into account the phenotypes of CMD with cognitive impairment already reported in the literature: 1. CMD patients with ␣-DG reduction on muscle biopsy. This group was further subdivided according to the phenotype reported and to the genetic findings. 2. CMD patients with laminin ␣2 deficiency and LAMA2 mutations, providing details of their MRI findings. 3. CMD with adducted thumbs, cerebellar hypoplasia, ptosis, and external ophthalmoplegia. 15 
4.
Other phenotypes that could not be included in any of the above.
Clinical data. Clinical data including presence of epilepsy, microcephaly, eye involvement, and CK levels were collected on a structured pro forma.
Cognitive assessment. Wechsler intelligence scales (Wechsler
Preschool and Primary Scale of Intelligence for patients between 4.5 and 6 years and Wechsler Intelligence Scale for Children-Revised for patients older than 6 years) were used to assess general intelligence. The IQs were classified according to the criteria suggested by the DSM-IV as borderline (IQ 70 -85), mild (IQ 55-70), moderate (IQ 40 -55), severe (IQ 25-40), or profound (IQ 20 -25) mental retardation. 16 In order to identify even minor cognitive difficulties, we also included patients with borderline results.
Brain MRI. Brain MRI were performed and the scans available were reviewed by 4 examiners (C.U., A.P., L.F., R.B.) paying particular attention to the presence of WM and cortical abnor-malities, cerebellar hypoplasia, or other cerebellar changes and brainstem abnormalities. The examiners were blind to the clinical phenotypes or the associated genotype.
Muscle biopsy.
Previously performed muscle biopsies, when available, were reassessed. Immunofluorescence analysis was performed using commercially available antibodies directed against both the carboxyl terminus (monoclonal antibody 1922, 80 kDa, Chemicon, Temecula, CA) (1:1,000) and the amino terminus (mouse monoclonal antibody NCL-merosin, 300 kDa, Novocastra) (1:100) of laminin ␣2 and using IIH6 or VIA4 -1 monoclonal antibodies (Upstate Biotechnology) for ␣-DG as described elsewhere. 17, 18 The ␣-DG and laminin ␣2 expression was interpreted according to criteria agreed upon by all centers and classified as normal, absent, or reduced. Cases with mild reductions were reviewed and classified by consensus of pathologists from the different centers.
Molecular genetic analyses. Molecular genetic analyses of
the genes associated with the forms of CMD with defective glycosylation of ␣-DG, namely POMT1 (Genbank accession number NM_007171.3), POMT2 (NM_013382.4), POMGnT1 (NM_017739.2), FKRP (NM_001039885.1), FKTN (NM_006731.2), and LARGE (NM_004737.3), and of LAMA2 (XM_011387), were performed according to methods described elsewhere. 13, 18 RESULTS Of the 160 cases with CMD available in the databases of the participating centers, 68 had normal cognitive development while the remaining 92 (58%) had cognitive difficulties. None of the patients with Ullrich CMD or rigid spine CMD related to SEPN1 mutations had cognitive impairment. Of the 92 patients who fulfilled the inclusion criteria, 9 had borderline, 25 mild, 20 moderate, 19 severe, and 18 profound cognitive impairment. In 1 patient, the level of cognitive impairment was not formally assessed, but school report and parent interview clearly revealed cognitive difficulties.
Brain MRI had been performed in 90 of the 92 patients with scans available for review in 78/92, while in 12 only a report was available. The remaining 2 patients only had CT scans. Sixty-four of 90 (71%) patients had structural brain abnormalities, another 4 (5%) had diffuse WM changes only, and 22 (24%) had normal brain MRI.
Epilepsy was present in 35/92 (38%) patients and all had MRI abnormalities: 33 had structural changes and 2 WM changes. The presence of epilepsy was reported in 25 of the 37 patients with severe and profound cognitive impairment (68%). Details of the correlations among MRI findings, cognitive impairment, and presence of epilepsy are summarized in table 1.
According to clinical, biopsy, and MRI findings, the cohort was classified as follows.
␣-Dystroglycanopathy. Seventy-three of the 92 patients (79%) had clinical, radiologic, and/or morphologic findings suggestive of ␣-dystroglycanopathy.
Brain MRI scans were available in 71 and showed structural brain changes in 51/71 (72%), while the remaining 20 (28%) had normal scans. Two patients did not give permission for brain MRI. All the patients with structural changes had cerebellar involvement, including cerebellar hypoplasia, cerebellar cysts, and, in 2 cases carrying POMT1 and POMT2 mutations, Chiari malformation type 1 (figure, A).
Epilepsy was present in 28 of the 73 (38%) patients and all had structural brain abnormalities. Correlations among MRI findings, cognitive impairment, and presence of epilepsy in this group are described in table 2.
Forty-two of these patients (58%) carried mutation in one of the known genes involved in CMD with ␣-DG glycosylation defects. All but 2 patients, carrying POMGnT1 mutations, have already been reported as part of a larger series of patients with ␣-DG with and without cognitive impairment. 13 Details of the correlation between genetic background and phenotype have already been reported and are summarized in tables 3 and 4.
Four of the 73 patients with reduced ␣-DG shared a strikingly similar phenotype characterized by CMD and cognitive impairment, microcephaly, cerebellar hypoplasia, feeding difficulties, and progressive myoclonic epilepsy. Mutations in the 6 known genes were ruled out in these cases that have recently been reported separately. 19 Laminin ␣2. Six patients (7%) had normal ␣-DG but reduced laminin ␣2 and 5 carried mutations in the LAMA2 genes. Three of the 5 with mutations had WM changes only, and the other 2 had cortical dysplasia and have been previously described. 5 The patient with no mutations on LAMA2 analysis had the typical WM changes and no mutations in ␣-DG genes (table 3) .
Epilepsy was present in 4/6 patients with 2 of the 4 presenting with WM changes without structural MRI abnormalities. The 4 patients presenting epilepsy showed a moderate cognitive impairment; in the other 2, it was mild (table 1).
Other cases. Thirteen patients (14%) had normal ␣-DG and laminin ␣2 expression. Eleven of the 13 had 
Abbreviations: ⅙ ϭ patients without epilepsy; • ϭ patients with epilepsy; CI ϭ cognitive impairment; WM ϭ white matter. a Three patients in whom MRI scans were not available or CI was not formally tested were excluded (n ϭ 89).
brain changes with significant overlap with those reported in the cases with ␣-DG deficiency. They were all screened for the known ␣-dystroglycanopathy genes but no mutation was found (table 3) . Two of the 11 had frontal cortical dysplasia resembling that observed in the cases with ␣-DG deficiency and muscle-eye-brain phenotype. They also had ocular involvement but with normal cerebellum on brain MRI, with normal size and no obvious cysts or other dysplastic features. CK levels were not grossly elevated (2 to 3 times normal values).
One had cerebellar vermis aplasia and another 2 had cerebellar hypoplasia.
Three had cerebral and cerebellar atrophy, associated with hydrocephalus in 1 of the 3. Two of them have already been reported (figure, B and C). 20 One child had hydrocephalus and a dysmorphic mesencephalon.
The remaining 2 have already been reported. They are siblings with a distinctive phenotype characterized by adducted thumbs, cerebellar hypoplasia, ptosis, and external ophthalmoplegia. 15 Epilepsy was present in 3 of these 13 patients, 1 presenting with frontal cortical dysplasia, 1 with cerebellar vermis aplasia, and the other with cerebral and cerebellar atrophy. In the first 2 cases, epilepsy was associated with severe cognitive impairment. DISCUSSION In this study, we evaluated for the first time the frequency of the different forms of CMD and cognitive impairment as part of a large multicentric cohort including all the pediatric tertiary neuromuscular centers in Italy. Cognitive impairment was found in over half of the overall group of patients with CMD (92/160, 58%). In 47 of our 92 patients (51%), we were able to find mutations in one of the known genes responsible for CMD forms. Our results confirmed previous evidence that in patients with CMD cognitive impairment is more frequently associated with structural brain changes (in 70% of our cohort), 4, 7, 8, 12, 13, 21 even though a normal brain MRI does not rule out the possibility to develop cognitive impairment.
We were able to broadly identify 3 subgroups: 1 with ␣-DG reduction, 1 with laminin ␣2 reduction, and a third group with normal ␣-DG and laminin ␣2.
Not surprisingly, 73 of the 92 patients had a reduction of ␣-DG. These patients, with 2 exceptions, were part of a recently reported larger Italian cohort of dystroglycanopathies with and without cognitive impairment. 13 In the present study, we only included the patients with cognitive impairment. The detection rate of mutations in the known genes in this subgroup was 58%, similar to that found in the overall cohort with ␣-DG reduction (56.5%), which in- 
Abbreviations: ⅙ ϭ patients without epilepsy; • ϭ patients with epilepsy; CI ϭ cognitive impairment; CMD-CRB ϭ congenital muscular dystrophy with cerebellar involvement; MEB ϭ muscle-eye-brain disease; WM ϭ white matter; WWS ϭ Walker-Walburg syndrome. a A patient in whom CI was not formally tested was excluded (n ϭ 70). cluded patients with normal cognitive development.
As recently reported, patients with cognitive impairment but normal brain MRI more often carried mutations in POMT1 and POMT2 and in a significant number of cases (14%) had no mutations in the known genes. Among patients with ␣-DG reduction but no mutations in the known genes, we were able to identify a new phenotype in 4 patients characterized by cognitive impairment, microcephaly, cerebellar hypoplasia, feeding difficulties, and severe myoclonic epilepsy. 19 We also reported the presence of cognitive impairment in patients with merosin-deficient CMD even though the correlation between clinical and imaging findings was somehow different from that previously reported. Classically, patients with LAMA2 mutations invariably have diffuse WM changes on brain MRI, but these are generally not associated with cognitive impairment or other overt signs of CNS involvement. Cognitive impairment has been previously reported mainly in cases with the concomitant presence of structural changes. [3] [4] [5] [6] [7] In our cohort, however, only 2 of the 6 cases with cognitive impairment had structural brain changes, while the other 4 had only the typical diffuse WM changes on MRI. In 2 of the 4 cases with WM changes only there was also severe epilepsy even if there was no obvious sign of cortical dysplasia on the scans.
Our systematic review of all cases of CMD and cognitive impairment allowed us to identify a number of cases (13/92, 14%) who did not fit into the previously described subgroups. This group is of interest as they share some clinical and radiologic features with patients with dystroglycanopathies, but have normal ␣-DG on muscle biopsy. Surprisingly 11 of the 13 had brain changes on MRI that were similar to those usually found in ␣-dystroglycanopathies.
Eight patients had cerebellar involvement, mainly hypoplasia, and another 2 had cortical dysplasia that was localized, similarly to ␣-dystroglycanopathies, in the frontal regions. The remaining patient had hydrocephalus and a dysmorphic mesencephalon.
It is also of interest that 8 of the 11 with structural brain changes and normal ␣-DG also had ocular involvement. These findings raise the question of differential diagnosis. Because of the similarity with ␣-dystroglycanopathies we screened all the 6 known genes even if ␣-DG was normal on muscle biopsy, but we could not detect any mutation. Interestingly, half of the patients had normal or only mildly elevated CK, with only 2 patients having very elevated CK as generally found in patients with ␣-DG reduction.
Two of these patients have previously been reported 20 before the discovery of ␣-DG and have a distinct phenotype with ataxic syndrome. In both, cerebellum appeared not only reduced in volume but also had enlarged interfolia, suggesting possible atrophy even though serial imaging failed to show any progression of the atrophy. Another 2 patients also had a distinct phenotype with cerebellar hypoplasia, adducted thumbs, ptosis, and external ophthalmoplegia, and have also been previously described. 15 Our study provides the first systematic populationbased study establishing the frequency of cognitive impairment in the different forms of CMD and a detailed description of different phenotypes.
We were unable to identify an association between mutations in individual genes and severity of cognitive impairment as mild, moderate, and severe cognitive impairment appeared to be present in association with each gene and also in the group with no mutations in the known genes. In contrast, not surprisingly, the severity of cognitive impairment appeared to be more related to the severity of brain Table 4 Phenotype description of the 71 individuals with ␣-dystroglycan reduction according to the genetic background
CMD-MR CMD-CRB MEB WWS
Additional phenotypes: Chiari malformation type 1, hydrocephalus, cerebral atrophy
▫ ◊ ⅙ Ⅲ Ⅲ Ⅲ Ⅲ Ⅲ ▫ ▫ ࡗ ⅙ Ⅲ
FKRP ◊ ⅙ ◊ ⅙ Large Ⅲ
Negative ⅙ ⅙ ⅙ ⅙ ⅙ ⅙ ⅙ ⅙ ⅙ ⅙ Ⅲ Ⅲ Ⅲ Ⅲ Ⅲ
• Ⅲ Ⅲ Ⅲ Ⅲ Ⅲ Ⅲ ▫ ◊ • X Ⅲ Ⅲ Ⅲ ⅙ • Abbreviations: ⅙ • ϭ presence of borderline or mild mental retardation alone (⅙) or with epilepsy (•); ◊ ࡗ ϭ presence of moderate mental retardation alone (◊) or with epilepsy (ࡗ); ▫ Ⅲ ϭ presence of severe or profound mental retardation alone (▫) or with epilepsy (Ⅲ); CMD-CRB ϭ congenital muscular dystrophy with cerebellar involvement; MEB ϭ muscle-eye-brain disease; MR ϭ mental retardation; WWS ϭ Walker-Walburg syndrome; X ϭ patient with level of cognitive impairment not formally tested and without epilepsy.
changes on MRI. Walker-Walburg syndrome and muscle-eye-brain phenotype were generally associated with the most severe cognitive impairment, while none of the patients with normal scans had severe or profound cognitive impairment. As this was a large multicentric study, also including cases for whom data could only be obtained from notes, we did not always have collected systematic cognitive or EEG findings and this limited the possibility to have better information on the correlation between the severity of cognitive impairment and epilepsy that was present in a third of the patients and always in cases with structural MRI abnormalities or WM changes.
A prospective study on the subgroup currently followed is in progress in order to obtain more detailed information on epilepsy and cognitive impairment in this cohort.
